Safety and tolerance of propranolol in neonates with severe infantile hemangiomas: a prospective study

Abstract Although the efficacy of propranolol for the treatment of infantile hemangiomas (IHs) has been well documented, there is a paucity of clinical data regarding the safety and tolerance of propranolol in neonates. A prospective study of 51 patients less than 30 days of age with severe IH was c...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Yi Ji, Siyuan Chen, Bo Xiang, Yang Yang, Liqing Qiu
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2017
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/7e46705eaa734207a9a43809fd136adb
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:7e46705eaa734207a9a43809fd136adb
record_format	dspace
spelling	oai:doaj.org-article:7e46705eaa734207a9a43809fd136adb2021-12-02T16:06:37ZSafety and tolerance of propranolol in neonates with severe infantile hemangiomas: a prospective study10.1038/s41598-017-01321-22045-2322https://doaj.org/article/7e46705eaa734207a9a43809fd136adb2017-05-01T00:00:00Zhttps://doi.org/10.1038/s41598-017-01321-2https://doaj.org/toc/2045-2322Abstract Although the efficacy of propranolol for the treatment of infantile hemangiomas (IHs) has been well documented, there is a paucity of clinical data regarding the safety and tolerance of propranolol in neonates. A prospective study of 51 patients less than 30 days of age with severe IH was conducted. All patients were admitted to the hospital for monitoring during initial propranolol treatment at day 0 with dose adjustments at days 7 and 28. Heart rate (HR), systolic blood pressure (SBP), diastolic blood pressure (DBP), blood glucose (BG) levels and potential side effects were evaluated during treatment. There were significant decreases in mean heart rate and SBP after the initiation of propranolol therapy (P < 0.05). In contrast, no significant differences in mean DBP and BG levels were observed after each dose during hospitalization (P > 0.05). Bradycardia and hypotension were noted in at least 1 recorded instance in 11.8% and 5.9% of patients, respectively. These hemodynamic changes were not persistent and were asymptomatic. Two patients who had a history of neonatal pneumonia reported severe bronchial hyperreactivity during treatment. This study demonstrated that propranolol administered to properly selected young infants was safe and well tolerated. However, close monitoring should be considered in high-risk young patients.Yi JiSiyuan ChenBo XiangYang YangLiqing QiuNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 7, Iss 1, Pp 1-8 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Yi Ji Siyuan Chen Bo Xiang Yang Yang Liqing Qiu Safety and tolerance of propranolol in neonates with severe infantile hemangiomas: a prospective study
description	Abstract Although the efficacy of propranolol for the treatment of infantile hemangiomas (IHs) has been well documented, there is a paucity of clinical data regarding the safety and tolerance of propranolol in neonates. A prospective study of 51 patients less than 30 days of age with severe IH was conducted. All patients were admitted to the hospital for monitoring during initial propranolol treatment at day 0 with dose adjustments at days 7 and 28. Heart rate (HR), systolic blood pressure (SBP), diastolic blood pressure (DBP), blood glucose (BG) levels and potential side effects were evaluated during treatment. There were significant decreases in mean heart rate and SBP after the initiation of propranolol therapy (P < 0.05). In contrast, no significant differences in mean DBP and BG levels were observed after each dose during hospitalization (P > 0.05). Bradycardia and hypotension were noted in at least 1 recorded instance in 11.8% and 5.9% of patients, respectively. These hemodynamic changes were not persistent and were asymptomatic. Two patients who had a history of neonatal pneumonia reported severe bronchial hyperreactivity during treatment. This study demonstrated that propranolol administered to properly selected young infants was safe and well tolerated. However, close monitoring should be considered in high-risk young patients.
format	article
author	Yi Ji Siyuan Chen Bo Xiang Yang Yang Liqing Qiu
author_facet	Yi Ji Siyuan Chen Bo Xiang Yang Yang Liqing Qiu
author_sort	Yi Ji
title	Safety and tolerance of propranolol in neonates with severe infantile hemangiomas: a prospective study
title_short	Safety and tolerance of propranolol in neonates with severe infantile hemangiomas: a prospective study
title_full	Safety and tolerance of propranolol in neonates with severe infantile hemangiomas: a prospective study
title_fullStr	Safety and tolerance of propranolol in neonates with severe infantile hemangiomas: a prospective study
title_full_unstemmed	Safety and tolerance of propranolol in neonates with severe infantile hemangiomas: a prospective study
title_sort	safety and tolerance of propranolol in neonates with severe infantile hemangiomas: a prospective study
publisher	Nature Portfolio
publishDate	2017
url	https://doaj.org/article/7e46705eaa734207a9a43809fd136adb
work_keys_str_mv	AT yiji safetyandtoleranceofpropranololinneonateswithsevereinfantilehemangiomasaprospectivestudy AT siyuanchen safetyandtoleranceofpropranololinneonateswithsevereinfantilehemangiomasaprospectivestudy AT boxiang safetyandtoleranceofpropranololinneonateswithsevereinfantilehemangiomasaprospectivestudy AT yangyang safetyandtoleranceofpropranololinneonateswithsevereinfantilehemangiomasaprospectivestudy AT liqingqiu safetyandtoleranceofpropranololinneonateswithsevereinfantilehemangiomasaprospectivestudy
_version_	1718384971295490048

Safety and tolerance of propranolol in neonates with severe infantile hemangiomas: a prospective study

Ejemplares similares